Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
Stable expression over 15 generations with rapid cell line development in just 3 months. Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
Predicted to enable protein tyrosine phosphatase activity. Predicted to be involved in nervous system development; signal transduction; and synaptic membrane adhesion. Predicted to act upstream of or within protein dephosphorylation. Predicted to be located in plasma membrane. Is expressed in Rohon-Beard neurons; lateral line ganglion; olfactory placode; and trigeminal ganglion. Human ortholog(s) of this gene implicated in coronary artery disease; diabetes mellitus; hypertension; and type 2 diabetes mellitus. Orthologous to human PTPRD (protein tyrosine phosphatase receptor type D). [provided by Alliance of Genome Resources, Feb 2025]